



Designation: **E2629—19** **E2629 – 20**

# Standard Guide for Verification of Process Analytical Technology (PAT) Enabled Control Systems<sup>1</sup>

This standard is issued under the fixed designation E2629; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon ( $\epsilon$ ) indicates an editorial change since the last revision or reapproval.

## 1. Scope

1.1 This guide describes the verification of process analytical technology (PAT) enabled control systems using a science- and risk-based approach. It establishes principles for determining the scope and extent of verification activities necessary to ensure that the PAT-enabled control system is fit for purpose, properly implemented, and functions as expected.

1.2 In this guide, a PAT-enabled control system is considered to be the system that adjusts the manufacturing process using timely measurements (that is, during processing) of attributes of raw and in-process materials to determine responses that assure the process remains within specified boundaries and minimizes variability in the output material. The overall aim of the PAT-enabled control system is to ensure product quality. The PAT-enabled control system of a manufacturing process provides the capability to determine the current status of the process and drive the process to ensure the output material has the desired quality characteristics. The control system should be able to respond to process variations in a timely manner, providing corrections that ensure that the process follows the desired process trajectory to reach the desired outcome. PAT-enabled control systems may use process models based on first principles understanding or empirical models derived from experimental investigations or both. In addition to automated controls, a PAT-enabled control system may include components where there is manual intervention.

1.3 Principles described in this guide may be applied regardless of the complexity or scale of the PAT-enabled control system or whether applied to batch or continuous processing, or both. The intention of this standard is to describe and support the implementation of a PAT enabled Control Strategy, as described in ICH Q8(R2).

1.4 The principles described in this guide are applicable to a PAT-enabled control system and also to its component subsystems. This guide does not cover the requirements for continuous quality verification of the overall process, which are covered in Guide [E2537](#), or for validation of PAT methods, which is covered in Guide [E2898](#).

1.5 For information on science- and risk-based approaches in the pharmaceutical industry, reference should be made to ICH Q8(R2), ICH Q9, and ICH Q10. For guidance on PAT systems in the pharmaceutical industry, reference should be made to FDA Guidance for Industry—PAT and FDA Guidance for Industry—Process Validation, as well as EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use and EU Guideline on Process Validation for Finished Products.

1.6 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.*

1.7 *This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.*

## 2. Referenced Documents

### 2.1 ASTM Standards:<sup>2</sup>

[E122 Practice for Calculating Sample Size to Estimate, With Specified Precision, the Average for a Characteristic of a Lot or Process](#)

<sup>1</sup> This guide is under the jurisdiction of ASTM Committee E55 on Manufacture of Pharmaceutical and Biopharmaceutical Products and is the direct responsibility of Subcommittee E55.01 on Process Understanding and PAT System Management, Implementation and Practice.

Current edition approved June 15, 2019 Aug. 1, 2020. Published July 2019 August 2020. Originally approved in 2011. Last previous edition approved in 2019 as E2629 – 19. DOI: [10.1520/E2629-19.10.1520/E2629-20](#).

<sup>2</sup> For referenced ASTM standards, visit the ASTM website, [www.astm.org](#), or contact ASTM Customer Service at [service@astm.org](#). For *Annual Book of ASTM Standards* volume information, refer to the [standard's Document Summary page](#) on the ASTM website.

**E2363** Terminology Relating to Process Analytical Technology in the Pharmaceutical Industry

**E2476** Guide for Risk Assessment and Risk Control as it Impacts the Design, Development, and Operation of PAT Processes for Pharmaceutical Manufacture

**iTeh Standards**  
**(<https://standards.iteh.ai>)**  
**Document Preview**

[ASTM E2629-20](#)

<https://standards.iteh.ai/catalog/standards/sist/f0719637-9d3e-4dc0-b565-94d1b74332bd/astm-e2629-20>

**E2500** Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment

**E2537** Guide for Application of Continuous Process Verification to Pharmaceutical and Biopharmaceutical Manufacturing

**E2898** Guide for Risk-Based Validation of Analytical Methods for PAT Applications

2.2 *Regulatory Guidance and Other Documents:*

**ICH Q2(R1)** Validation of Analytical Procedures: Text and Methodology<sup>3</sup>

**ICH Q8(R2)** Pharmaceutical Development<sup>3</sup>

**ICH Q9** Risk Management<sup>3</sup>

**ICH Q10** Pharmaceutical Quality System<sup>3</sup>

**FDA Guidance for Industry—PAT A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance**<sup>4</sup>

**FDA Guidance for Industry—Process Validation General Principles and Practices**<sup>4</sup>

**EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Annex 15: Qualification and Validation**<sup>5</sup>

**EU Guideline on Process Validation for Finished Products**<sup>5</sup>

### 3. Terminology

3.1 *Definitions*—See also Terminology **E2363** for other PAT terms.

3.1.1 *attribute, n*—characteristic or inherent quality or feature. **E2363**

3.1.2 *control model, n*—procedure or mathematical expression (algorithm) that uses the outputs of the process model combined with any other data inputs required to calculate values for the critical control parameters for the process; it uses input data from the process to generate an actionable command or commands that are issued to the control system.

3.1.2.1 *Discussion*—

The control model may define what actions to take when specific attribute values are detected. The control model may be complex or simple, for example, it may be predictive, as in the case of model-based control (MBC) in which it is desired to manage the operation of the process along a particular trajectory; it may be a single proportional integral derivative (PID) loop controller; or it may be anything in between.

3.1.3 *control system, n*—system that responds to inputs signals from the process, its associated equipment, other programmable systems or an operator or both, and generates output signals causing the process and its associated equipment to operate in the desired manner.

3.1.4 *measurement system, n*—system of sensors, instruments, and/or analyzers that collects signals generated by passive or active interaction with process material or process equipment and converts those signals into data.

3.1.5 *parameter, n*—measureable or quantifiable characteristic of a system or process. **E2363**

3.1.6 *process model, n*—mathematical expression (algorithm) that uses data from the measurement system(s) (inputs to the process model) to calculate the value of one or more of the process material attributes (outputs from the process model) at the time the measurement was taken.

3.1.6.1 *Discussion*—

The process model typically will have to handle sets of orthogonal or nonorthogonal attributes. The mathematical algorithm will ideally represent first-principle understanding of the process being modelled. However, when sufficient first-principles understanding is unavailable, an empirical model may also be used.

3.2 *Acronyms:*

3.2.1 *CCP*—Critical control parameter

3.2.2 *CPP*—Critical process parameter

3.2.3 *CQA*—Critical quality attribute

<sup>3</sup> Available from International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), ICH Secretariat, c/o IFPMA, 15 ch. Louis-Dunant, P.O. Box 195, 1211 Geneva 20, Switzerland, <http://www.ich.org>.

<sup>4</sup> Available from Office of Training and Communication, Division of Drug Information, HFD-240, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, <http://www.fda.gov>.

<sup>5</sup> Available from the European Commission (European Union (EU)), <https://ec.europa.eu>.

<sup>6</sup> *Perry's Handbook of Chemical Engineering*, see BPCS—Basic Process Control System, McGraw Hill, 2007.

- 3.2.4 *CQV*—Continuous quality verification
- 3.2.5 *FDA*—Food and Drug Administration
- 3.2.6 *ICH*—International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
- 3.2.7 *ISA*—International Society of Automation
- 3.2.8 *LOD*—Limit of detection
- 3.2.9 *MBC*—Model-based control
- 3.2.10 *MVA*—Multivariate analysis
- 3.2.11 *PAT*—Process analytical technology
- 3.2.12 *PID*—Proportional integral derivative
- 3.2.13 *PP*—Process parameter
- 3.2.14 *QA*—Quality attribute

**4. Summary of Practice**

4.1 To aid reader understanding, a diagram of the data flows in a PAT-enabled control system is shown in Fig. 1. The diagram shows how process and control models can be used in a closed loop control paradigm (with decisions being made based on action limits set in the control model) but also for feed-forward control to downstream process steps/operations.

4.2 Fig. 2 shows how the quality attributes (QAs), noncritical as well as critical, are fed into the control model via the process model. Each process has process parameters (PPs). Based on process understanding, some PPs are held static and others are subject to dynamic adjustment. Some of the PPs directly or indirectly impact critical quality attributes (CQAs) and these PPs are called critical process parameters (CPPs). When the CPPs (which may be fixed or adjustable) are dynamically adjusted as a result of information generated by the process and control models, they are called critical control parameters (CCPs). Revised CCP settings are transmitted in real time to the manufacturing equipment where they change the conditions of manufacture for the product.

4.3 *Control Strategy:*




FIG. 1 Data Flows for a PAT-Enabled Control System




FIG. 2 Relationship Between Quality Attributes and the Control System

4.3.1 The control strategy should be designed to control the quality of the product in response to potential variations in the process, equipment conditions, incoming raw materials, or environmental factors over time. Control strategy implementations generally can be categorized into three types:<sup>7</sup>

4.3.1.1 *Level 1: Quality Assurance by Means of Application of Dynamic or Adaptive Process Control System:*

(1) A Level 1 control strategy utilizes Dynamic or Adaptive Process Control System to monitor and control the quality attributes of materials in real-time.

(2) In Dynamic or Adaptive Process Control, system process parameters are monitored and may be adjusted in response to disturbances to ensure that the quality attributes consistently conform to the established acceptance criteria.

(3) The successful application of a Dynamic or Adaptive Process Control system represents a high degree of product and process understanding as the design of an engineering control system entails expressing the dynamic relationships among process parameters, raw material and product attributes in a quantitative and predictive manner.

(4) The ability of a Dynamic or Adaptive Process Control System to compensate for variation in the raw material attributes or external disturbances to the process condition significantly reduces the risk of producing of out of specification material and hence the requirement for routine segregation/diversion of out-of-specification is also reduced.

(5) Statistical monitoring tools, for example Univariate or Multivariate SPC, may be used to demonstrate that the Dynamic or Adaptive Process control system is ensuring that the process is operating in a State of Control where there is a very low probability of out of specification being produced.

(6) Successful implementation of a Dynamic or Adaptive Process Control system directly supports a real-time release strategy.

4.3.1.2 *Level 2: Quality Assurance by Means of Operation Within an Established Design Space and Confirmatory End Product and In-Process Material Testing:*

(1) Product Quality may be assured by combination of appropriate end product testing together with appropriate monitoring of controlled raw material attributes and process parameters.

(2) The product and process understanding obtained through the establishment of a multivariate design space facilitates the identification of potential sources of raw material and process variability that can impact product quality.

(3) Understanding the impact that variability from these sources has on in-process materials, downstream processing, and drug product quality provides an opportunity to shift controls upstream and to reduce the reliance on end-product testing.

(4) The absence of real time corrective action within the control system increases the probability for production of out of specification material and hence requires appropriate mechanisms for ensuring rejection/diversion of any out-of-specification product.

4.3.1.3 *Level 3: Quality Assurance by Means of Operation Within a Validated and Tightly Constrained Material Attributes and Process Parameters and Release Based on End Product Testing:*

(1) A Level 3, Control Strategy does not use PAT for either feedforward or feedback control and is therefore outside the scope of this standard. Process analytics may however be used as a measurement of intermediate CQA as a form of in-process control (to verify the process has remained in a state of control) or in place of end-of-line testing.

5. Significance and Use

5.1 This guide supports the principles of Guide E2500 and extends these principles to the verification of PAT-enabled control systems.

<sup>7</sup> “Modernizing Pharmaceutical Manufacturing: From Batch to Continuous Production,” *Journal of Pharmaceutical Innovation*, Vol 10, No 3, September 2015.